269 related articles for article (PubMed ID: 19524867)
21. Evaluation of relaxin's antifibrotic action by SELDI-TOF mass spectrometry-based profiling of relaxin knockout mice, a model of progressive fibrosis.
Giannakis E; Macris M; Chan L; Tregear GW; Samuel CS; Wade JD
Ann N Y Acad Sci; 2009 Apr; 1160():350-2. PubMed ID: 19416218
[TBL] [Abstract][Full Text] [Related]
22. Peptide hormone relaxin: from bench to bedside.
Jelinic M; Marshall SA; Stewart D; Unemori E; Parry LJ; Leo CH
Am J Physiol Regul Integr Comp Physiol; 2018 Jun; 314(6):R753-R760. PubMed ID: 29412692
[TBL] [Abstract][Full Text] [Related]
23. Biology of primate relaxin: a paracrine signal in early pregnancy?
Hayes ES
Reprod Biol Endocrinol; 2004 Jun; 2():36. PubMed ID: 15200675
[TBL] [Abstract][Full Text] [Related]
24. Relaxin and castration in male mice protect from, but testosterone exacerbates, age-related cardiac and renal fibrosis, whereas estrogens are an independent determinant of organ size.
Hewitson TD; Zhao C; Wigg B; Lee SW; Simpson ER; Boon WC; Samuel CS
Endocrinology; 2012 Jan; 153(1):188-99. PubMed ID: 22028442
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects of relaxin: from basic science to clinical therapy.
Du XJ; Bathgate RA; Samuel CS; Dart AM; Summers RJ
Nat Rev Cardiol; 2010 Jan; 7(1):48-58. PubMed ID: 19935741
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary fibrosis in scleroderma: report of a case with pulmonary function studies to evaluate corticosteroid and relaxin therapy.
TRANQUADA RE; SIMMONS DH; MILLER JH
Arch Intern Med; 1960 Apr; 105():607-12. PubMed ID: 13839183
[No Abstract] [Full Text] [Related]
27. Role of protein kinase C β₂ in relaxin-mediated inhibition of cardiac fibrosis.
Su W; Wang P; Chen H; Li H
J Endocrinol Invest; 2014 Jun; 37(6):559-64. PubMed ID: 24729283
[TBL] [Abstract][Full Text] [Related]
28. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
[TBL] [Abstract][Full Text] [Related]
29. Relaxin and fibrosis: Emerging targets, challenges, and future directions.
Kanai AJ; Konieczko EM; Bennett RG; Samuel CS; Royce SG
Mol Cell Endocrinol; 2019 May; 487():66-74. PubMed ID: 30772373
[TBL] [Abstract][Full Text] [Related]
30. Relaxin regulates collagen overproduction associated with experimental progressive renal fibrosis.
Samuel CS; Mookerjee I; Masterson R; Tregear GW; Hewitson TD
Ann N Y Acad Sci; 2005 May; 1041():182-4. PubMed ID: 15956704
[TBL] [Abstract][Full Text] [Related]
31. Relaxin: a pregnancy hormone as central player of body fluid and circulation homeostasis.
Dschietzig T; Stangl K
Cell Mol Life Sci; 2003 Apr; 60(4):688-700. PubMed ID: 12785716
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Relaxin Pathway for Liver Disease Treatment.
Bennett RG
Eur Med J Hepatol; 2018 May; 6(1):80-87. PubMed ID: 31360529
[TBL] [Abstract][Full Text] [Related]
33. Relaxin and renal fibrosis.
Becker GJ; Hewitson TD
Kidney Int; 2001 Mar; 59(3):1184-5. PubMed ID: 11231378
[No Abstract] [Full Text] [Related]
34. The relaxin gene-knockout mouse: a model of progressive fibrosis.
Samuel CS; Zhao C; Bathgate RA; DU XJ; Summers RJ; Amento EP; Walker LL; McBurnie M; Zhao L; Tregear GW
Ann N Y Acad Sci; 2005 May; 1041():173-81. PubMed ID: 15956703
[TBL] [Abstract][Full Text] [Related]
35. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies specific for rat relaxin. I. Production and characterization of monoclonal antibodies that neutralize rat relaxin's bioactivity in vivo.
Guico-Lamm ML; Voss EW; Sherwood OD
Endocrinology; 1988 Nov; 123(5):2472-8. PubMed ID: 3168929
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
Seibold JR; Korn JH; Simms R; Clements PJ; Moreland LW; Mayes MD; Furst DE; Rothfield N; Steen V; Weisman M; Collier D; Wigley FM; Merkel PA; Csuka ME; Hsu V; Rocco S; Erikson M; Hannigan J; Harkonen WS; Sanders ME
Ann Intern Med; 2000 Jun; 132(11):871-9. PubMed ID: 10836913
[TBL] [Abstract][Full Text] [Related]
38. The physiological effects of relaxin during pregnancy: studies in rats and pigs.
Sherwood OD; Downing SJ; Guico-Lamm ML; Hwang JJ; O'Day-Bowman MB; Fields PA
Oxf Rev Reprod Biol; 1993; 15():143-89. PubMed ID: 8336976
[TBL] [Abstract][Full Text] [Related]
39. Understanding relaxin signalling at the cellular level.
Valkovic AL; Bathgate RA; Samuel CS; Kocan M
Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
[TBL] [Abstract][Full Text] [Related]
40. The relaxin gene knockout mouse: a model of progressive scleroderma.
Samuel CS; Zhao C; Yang Q; Wang H; Tian H; Tregear GW; Amento EP
J Invest Dermatol; 2005 Oct; 125(4):692-9. PubMed ID: 16185267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
